Hikma completes acquisition of Teligent sterile injectable assets

London, 3 February 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that, following its announcement on 17 January that it had agreed to acquire the Canadian assets of Teligent Inc. for $45.75 million, this transaction has now completed.

Press Release Corporate 3 February 2022

Text 1

The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Riad Mishlawi, President of Hikma Injectables, commented, “The completion of this acquisition expands Hikma’s presence in the highly attractive Canadian injectables market, bringing a strong portfolio of sterile injectable products, as well as strengthening our pipeline.  We are excited to bring these important products to our Canadian customers and their patients.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.